Eikon Therapeutics, Inc. Common Stock (EIKN) Stock

About Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.

Eikon Therapeutics, Inc. Common Stock is led by CEO Roger Perlmutter, employs 484 people, headquartered in US, publicly traded since 2026.

Eikon Therapeutics, Inc. Common Stock (EIKN) stock trades at $9.29 with a market capitalization of $502.95M. The stock is valued at a price-to-earnings (P/E) ratio of -3.10, price-to-book of 0.91, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.90 and $17.40, and currently trades 46.6% below its 52-week high.

On profitability, Eikon Therapeutics, Inc. Common Stock generates a return on equity (ROE) of 43.07% — well above the market average, a sign of a high-quality business, return on capital employed of -21.16%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: eikontx.com